Mycophenolate mofetil following rituximab in children with steroid-resistant nephrotic syndrome

Pediatrics

Volumn 136, Issue 1, 2015, Pages e132-e139

  Basu, Biswanath ^a   Mahapatra, T K S ^a   Mondal, Nirmal ^a  

^a NRS MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLATE MOFETIL; RITUXIMAB; CD20 ANTIGEN; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADOLESCENT; ARTICLE; B LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CONGENITAL NEPHROTIC SYNDROME; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FOCAL GLOMERULOSCLEROSIS; HUMAN; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REMISSION; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; DRUG COMBINATION; FOLLOW UP; NEPHROTIC SYNDROME; PRESCHOOL CHILD; TIME;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYCOPHENOLIC ACID; NEPHROTIC SYNDROME; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84934289312     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2015-0486     Document Type: Article

References (23)

1. Lombel RM, Hodson EM, Gipson DS; Kidney Disease: Improving Global Outcomes. Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. Pediatr Nephrol. 2013;28(3):409-414
2. Garin EH, Orak JK, Hiott KL, Sutherland SE. Cyclosporine therapy for steroid-resistant nephrotic syndrome. A controlled study. Am J Dis Child. 1988;142(9):985-988
3. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol. 1996;7(1):56-63
4. Ponticelli C, Rizzoni G, Edefonti A, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 1993;43(6): 1377-1384
5. Gipson DS, Trachtman H, Kaskel FJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011;80(8): 868-878
6. International Study of Kidney Disease in Children; Report of the International Study of Kidney Disease in Children. Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International Study of Kidney Disease in Children. Lancet. 1974;2(7878):423-427
7. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1996;10(5):590-593
8. Gulati A, Sinha A, Gupta A, et al. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int. 2012;82(10):1130-1135
9. Gulati A, Sinha A, Jordan SC, et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and-dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol. 2010;5(12):2207-2212
10. Prytuła A, Iijima K, Kamei K, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol. 2010;25(3):461-468
11. Otukesh H, Hoseini R, Rahimzadeh N, Fazel M. Rituximab in the treatment of nephrotic syndrome: a systematic review. Iran J Kidney Dis. 2013;7(4):249-256
12. Basu B. Ofatumumab for rituximab-resistant nephrotic syndrome. N Engl J Med. 2014;370(13):1268-1270
13. Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629-637
14. Kamei K, Ito S, Nozu K, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009;24(7):1321-1328
15. Fujinaga S, Hirano D, Nishizaki N, et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol. 2010;25(3):539-544
16. Guigonis V, Dallocchio A, Baudouin V, et al. Rituximab treatment for severe steroid-or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008; 23(8):1269-1279
17. Sellier-Leclerc AL, Macher MA, Loirat C, et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2010;25(6):1109-1115
18. Thaunat O, Patey N, Gautreau C, et al. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation. 2008;85(11):1648-1653
19. Amemiya N, Takei T, Kojima C, Nokiba H, Itabashi M, Nitta K. Induction of remission following a single dose of rituximab alone in a patient with minimal change nephrotic syndrome. Clin Exp Nephrol. 2011;15(6):933-936
20. Filler G, Huang SH, Sharma AP. Should we consider MMF therapy after rituximab for nephrotic syndrome? Pediatr Nephrol. 2011;26(10):1759-1762
21. Ito S, Kamei K, Ogura M, et al. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2011;26(10):1823-1828
22. Sharma AP, Filler G. Role of mycophenolate mofetil in remission maintenance after a successful response to rituximab. Pediatr Nephrol. 2009;24(2): 423-424
23. Gellermann J, Weber L, Pape L, Tönshoff B, Hoyer P, Querfeld U; Gesellschaft für Pädiatrische Nephrologie (GPN). Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol. 2013;24(10):1689-1697